GSK4027 |
Antagonist of KAT2B, KAT2A
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| KAT2B |
|
|
| KAT2A |
|
|
Antagonist
50 nM - 1 uM
Selectivity
In Vitro Selectivity Assessment
Potency: Ki - BRPF3: 100 nM, BRD1: 110 nM, FALZ: 130 nM, BRPF1: 140 nM
Potency Assay Off-Target:
BROMOscan assay run at DiscoverX. In the assay, PCAF and GCN5: Ki=1.4 nM, hence >70 fold window to ...
Selectivity Assessment Description:
BROMOscan assay run at DiscoverX. In the assay, PCAF and GCN5: Ki=1.4 nM, hence >70 fold window to o ...
Potency Cellular
In Vitro
KAT2B
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.6b01566
KAT2A
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.6b01566
Negative Control Compounds
GSK4028
Orthogonal Probes def
L-Moses
Chemical Information
| Molecular Formula | C17H21BrN4O |
| SMILEs | CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccccc2)C1 |
| InChI | InChI=1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1 |
| Molecular weight | 376.09 Da |
| AlogP | 2.4425999999999997 |
| HBond acceptors | 5 |
| HBond donors | 1 |
| Atoms | 44 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.